Tech
OpenAI Buys Orchestra Bio to Push Rosalind From Lab Science Into Drug Program Operations
OpenAI acquired Orchestra Bio and folds its drug-program agents into Rosalind, moving its life-sciences push from lab reasoning into operations.
Read the full discussion on HackerNoon
This article was aggregated from HackerNoon. Click to join the conversation.
View on HackerNoon
Related Trends in Tech
How to Trace AI Agent Decisions Across Blockchain Transactions
DeepSeek's Super-Agent Moves the Attention Bottleneck From Your Feed to Your Agents
ODF vs. Managed Block Storage on IBM Cloud: How I Model the Tradeoff for Stateful Workloads
The Big Change AI Brought In My Scattered Life - I Had Money In My Bank, But I Was Crying At 2 AM
Salesforce Pays $5.66B for Braze, Buying the Rival That Outran Marketing Cloud
Stripe Pay Turns Stripe Handles Into Free, Instant B2B Transfers